MISSISAUGA, ON - GSK’s AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 50-59 years of age who are at increased risk for RSV disease.2 In Canada, the vaccine was previously approved for use in adults aged 60 and older and is strongly recommended by the National Advisory Committee on Immunization (NACI) for all adults 75 years and older and those aged 60 and above in nursing homes and other chronic care facilities. NACI also recommends that adults aged 60-74 years may consider RSV vaccination in consultation with a health care provider.3
\nA systematic review of studies in the US showed that RSV is estimated to cause 42,000 hospitalizations* each year in adults aged 50-64 years old.4 Further, among Canadian adults aged 50 and older hospitalized with RSV, about 98 per cent have at least one chronic condition.5 Adults with chronic medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, heart failure and diabetes, are at increased risk for severe consequences from an RSV infection compared to those without these conditions.6,7 RSV can exacerbate these conditions and lead to pneumonia, hospitalization, or death.8
\nMichelle Horn, Interim Country Medical Director, GSK, said: “The natural age-related decline in immune function we all experience, which can increase our vulnerability to viruses like RSV, becomes more evident the older we get. Not surprisingly, incidence of RSV-associated hospitalizations in adults starts to increase at the age of 50. For adults with underlying medical conditions, RSV can worsen these conditions and lead to serious consequences. We are proud to be the first to provide a vaccine to help protect Canadians aged 50-59 at increased risk of lower respiratory tract disease caused by RSV.”
\nThe expanded age indication is based on the positive results from a phase III trial [NCT05590403] evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to underlying medical conditions.
\nApproval of an expanded age indication for AREXVY in Canada follows similar approvals in the US and the EU. GSK has also filed regulatory submissions to extend the use of its RSV vaccine to adults aged 50-59 at increased risk in Japan and other geographies with regulatory decisions undergoing review. Trials evaluating the immunogenicity and safety of the vaccine in adults aged 18-49 at increased risk and immunocompromised adults aged 18 and over are expected to read out later in 2024. The safety and effectiveness of Arexvy in adults aged 18-49 at increased risk for RSV disease and immunocompromised adults aged 18 and over are still under investigation and authorization has not yet been granted in any country.
\nAbout Arexvy
\nArexvy is currently approved in Canada for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older, and in adults 50 through 59 years of age who are at increased risk for RSV disease.
\nRespiratory syncytial virus vaccine, adjuvanted, contains recombinant glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01E adjuvant.
\nThe GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc. STIMULON is a trademark of SaponiQx Inc., a subsidiary of Agenus.
\nAbout the NCT05590403 trial
\nNCT05590403 is a phase III, placebo-controlled, observer-blind, randomized, multi-country immunogenicity trial to evaluate the non-inferiority of the immune response and evaluate safety in participants aged 50 to 59, including those at increased risk for RSV-LRTD compared to older adults aged 60 years and above after a single dose of GSK’s RSV vaccine.
\nThe study assessed the immune response in participants aged 50 to 59 with pre-defined stable chronic diseases leading to an increased risk for RSV disease (n=570). Immune responses in a broader group of participants aged 50-59 years without these pre-defined chronic diseases (n=570) were also evaluated compared to adults aged 60 and older (n=380). The trial’s primary endpoints were RSV-A and RSV-B neutralization titers of both groups at one month after the vaccine administration compared to adults aged 60 and older. There were also safety and immunogenicity secondary and tertiary endpoints. Safety and reactogenicity data were consistent with results from the initial AReSVi-006 data read out. The most common local adverse event was pain. The most common systemic adverse events were fatigue, myalgia, and headache, which were largely transient and mild to moderate in intensity.
\nResults from this trial have been presented at the ACIP meeting of October 2023 and at ReSVinet in February 2024, and have been published in a peer-reviewed medical journal. The data are being submitted to other regulators to support potential label expansions.
\nAbout the NCT04886596 trial
\nArexvy is the only RSV vaccine with efficacy and safety data available through three full seasons. These new data from the AReSVi-006 (Adult Respiratory Syncytial Virus, NCT04886596) were presented at the CHEST Annual Meeting, organized by the American College of Chest Physicians, on October 8, 2024.
\nAbout RSV in adults
\nRSV is a common contagious virus affecting the lungs and breathing passages. Adults can be at increased risk for RSV disease due to comorbidities, immune compromised status, or advanced age.8 RSV can exacerbate conditions, including COPD, asthma, and chronic heart failure and can lead to severe outcomes, such as pneumonia, hospitalization, and death.8 According to studies conducted in the US, RSV is estimated to cause approximately 177,000 hospitalizations in adults 65 years and older6 and 42,000 in adults aged 50-64 years old.4
\nThe Product Monograph, posted at www.ca.gsk.com, should be consulted for complete administration and safety information.
\nAbout GSK
\nGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.ca.
\nReferences
\nSwitch to dark mode to head towards a more sustainable world together. More info.
"},"globalSiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"locationSelector":{"text":"Location selector","href":"/en-ca/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-ca/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-ca/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-ca/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"At a glance","url":"/en-ca/company/at-a-glance/","nodes":[],"isActive":false},{"title":"Canada leadership team","url":"/en-ca/company/canada-leadership-team/","nodes":[],"isActive":false},{"title":"Policies","url":"/en-ca/company/policies/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global Outstanding people","image":{"src":"/media/l20f4brn/navthumb-web09-header-gskh_2_2022_smtspc_37_hess.jpg?rxy=0.355,0.36888888888888888&width=329&height=185&format=webp&quality=100&v=1dbf19a8f7504b0","alt":"Man smiling during a meeting","darkModeSrc":"/media/l20f4brn/navthumb-web09-header-gskh_2_2022_smtspc_37_hess.jpg?rxy=0.355,0.36888888888888888&width=329&height=185&format=webp&quality=90&v=1dbf19a8f7504b0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/outstanding-people/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global policy positions","image":{"src":"/media/zx5kpb4m/gsk_texture_fluid_03_a_cmyk_web-size.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a9142e6e0","alt":"Orange texture","darkModeSrc":"/media/zx5kpb4m/gsk_texture_fluid_03_a_cmyk_web-size.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a9142e6e0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/policy-positions","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-ca/innovation/","nodes":[{"title":"Therapeutic areas","url":"/en-ca/innovation/therapeutic-areas/","nodes":[],"isActive":false},{"title":"Trials","url":"/en-ca/innovation/trials/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global pipeline","image":{"src":"/media/xskjorin/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a91879100","alt":"Science experiment","darkModeSrc":"/media/xskjorin/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a91879100"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/innovation/pipeline/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global Behind the science magazine","image":{"src":"/media/ksueo3le/immuno-oncology-science-image.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a8b311970","alt":"3D rendering of immuno-oncology cells","darkModeSrc":"/media/ksueo3le/immuno-oncology-science-image.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a8b311970"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/behind-the-science-magazine/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-ca/products/","nodes":[{"title":"Products A-Z","url":"/en-ca/products/products-a-z/","nodes":[],"isActive":false},{"title":"Stiefel - Dermatology","url":"/en-ca/products/stiefel-dermatology/","nodes":[],"isActive":false},{"title":"Report a possible side effect","url":"/en-ca/products/report-a-possible-side-effect/","nodes":[],"isActive":false},{"title":"Patient Support and Healthcare Support Services","url":"/en-ca/products/patient-support-and-healthcare-support-services/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Report a possible side effect","image":{"src":"/media/0otczyps/web03-header-stvg_2_2022_port_5_hess_nav.jpg?rxy=0.53,0.48444444444444446&width=329&height=185&format=webp&quality=100&v=1dbf19a8dba8370","alt":"Woman in a labcoat smiling at the camera","darkModeSrc":"/media/0otczyps/web03-header-stvg_2_2022_port_5_hess_nav.jpg?rxy=0.53,0.48444444444444446&width=329&height=185&format=webp&quality=90&v=1dbf19a8dba8370"},"link":{"text":"Featured section","href":"/en-ca/products/report-a-possible-side-effect/","openInNewWindowText":null}},{"text":"GSKPro","image":{"src":"/media/i5mft2xn/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?rxy=0.48,0.23555555555555555&width=329&height=185&format=webp&quality=100&v=1dbf19a8e994ab0","alt":"Two people hanging out together in front of an orange background","darkModeSrc":"/media/i5mft2xn/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?rxy=0.48,0.23555555555555555&width=329&height=185&format=webp&quality=90&v=1dbf19a8e994ab0"},"link":{"text":"Featured website","href":"https://gskpro.com/en-ca/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-ca/responsibility/","nodes":[{"title":"Inclusion","url":"/en-ca/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"Ethical standards","url":"/en-ca/responsibility/ethical-standards/","nodes":[{"title":"Engaging with healthcare professionals","url":"/en-ca/responsibility/ethical-standards/engaging-with-healthcare-professionals/","nodes":[],"isActive":false},{"title":"Transparency reporting","url":"/en-ca/responsibility/ethical-standards/transparency-reporting/","nodes":[],"isActive":false},{"title":"Grants and donations","url":"/en-ca/responsibility/ethical-standards/grants-and-donations/","nodes":[],"isActive":false}],"isActive":false},{"title":"Charitable investments in Canada","url":"/en-ca/responsibility/charitable-investments-in-canada/","nodes":[],"isActive":false},{"title":"Accessibility","url":"/en-ca/responsibility/accessibility/","nodes":[{"title":"GSK’s Multi-Year Accessibility Plan","url":"/en-ca/responsibility/accessibility/gsk-s-multi-year-accessibility-plan/","nodes":[],"isActive":false}],"isActive":false},{"title":"Patient group funding","url":"/en-ca/responsibility/patient-group-funding/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Ethical standards","image":{"src":"/media/uxlkxzrj/ware_3_2022_prodqc_38_hess-1.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a8db07150","alt":"Group working together in a lab","darkModeSrc":"/media/uxlkxzrj/ware_3_2022_prodqc_38_hess-1.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a8db07150"},"link":{"text":"Featured section","href":"/en-ca/responsibility/ethical-standards/","openInNewWindowText":null}},{"text":"Global responsibility","image":{"src":"/media/olhgq5am/stvg_2_2022_smtlab_2_hess-1920x1080px.jpeg?rxy=0.41851106639839036,0.37764350453172207&width=329&height=185&format=webp&quality=100&v=1dbf19a8dc8db50","alt":"Man adjusting glasses working on a computer","darkModeSrc":"/media/olhgq5am/stvg_2_2022_smtlab_2_hess-1920x1080px.jpeg?rxy=0.41851106639839036,0.37764350453172207&width=329&height=185&format=webp&quality=90&v=1dbf19a8dc8db50"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/responsibility/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-ca/media/","nodes":[{"title":"Press releases","url":"/en-ca/media/press-releases/","nodes":[],"isActive":true},{"title":"Media contacts","url":"/en-ca/media/media-contacts/","nodes":[],"isActive":false},{"title":"Resource library","url":"/en-ca/media/resource-library/","nodes":[],"isActive":false}],"isActive":true,"promos":[{"text":"Global press releases","image":{"src":"/media/zyvhqfdo/gsk-house-view.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a9120dff0","alt":"Artwork in GSK Building","darkModeSrc":"/media/zyvhqfdo/gsk-house-view.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a9120dff0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/media/press-releases/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-ca/careers/","nodes":[{"title":"Life at GSK","url":"/en-ca/careers/life-at-gsk/","nodes":[],"isActive":false},{"title":"Experienced professionals","url":"/en-ca/careers/experienced-professionals/","nodes":[],"isActive":false},{"title":"Early careers","url":"/en-ca/careers/early-careers/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global how we hire","image":{"src":"/media/sbrno3h2/gsk_rix_24_10_18_p_d2_s4_064-how-we-hire-1920x960px.jpg?rxy=0.579476861167002,0.32661290322580644&width=329&height=185&format=webp&quality=100&v=1dbf19a8f7fb310","alt":"People talking together in a meeting","darkModeSrc":"/media/sbrno3h2/gsk_rix_24_10_18_p_d2_s4_064-how-we-hire-1920x960px.jpg?rxy=0.579476861167002,0.32661290322580644&width=329&height=185&format=webp&quality=90&v=1dbf19a8f7fb310"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/how-we-hire/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global future leaders program","image":{"src":"/media/vgal0nno/gskh-2-2022-smtspc-11-hess-future-leaders-graduate-programme-1920x960px.jpg?rxy=0.42655935613682094,0.3911290322580645&width=329&height=185&format=webp&quality=100&v=1dbf19a8f2d4d50","alt":"Two people conversing together in an office","darkModeSrc":"/media/vgal0nno/gskh-2-2022-smtspc-11-hess-future-leaders-graduate-programme-1920x960px.jpg?rxy=0.42655935613682094,0.3911290322580645&width=329&height=185&format=webp&quality=90&v=1dbf19a8f2d4d50"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/early-talent/future-leaders-graduate-programme","target":"_blank","openInNewWindowText":"Opens in a new window"}}]}],"skipToContent":null,"skipToSearch":null,"typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=5769","searchFieldPlaceholderText":"Enter a search term...","searchPage":"/en-ca/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"This website is intended for visitors looking for information on GSK Canada. Other market sites can be reached by visiting our location selector.
\n© 2001-2026 GSK plc. All rights reserved. Trademarks are owned by or licensed to the GSK group of companies.
\nGSK plc. Registered in England and Wales No. 3888792.
\nGlaxoSmithKline Inc. 100 Milverton Drive, Suite 800, Mississauga, ON L5R 4H1
","modernSlaveryStatement":{"name":"GSK Modern Slavery Act Statement 2023","url":"/media/iwinetmy/modern-slavery-act-statement-2023.pdf","fileExtension":"PDF","fileSize":"154.2KB","type":"file","target":"_blank","openInNewWindowText":"Opens in a new window"},"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"https://twitter.com/gskca","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on X","customIcon":null,"showPopupMenu":false,"type":"X"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Facebook","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Youtube","customIcon":null,"showPopupMenu":false,"type":"Youtube"},{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on LinkedIn","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gsk/","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"GSK Global website","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Market website selector","href":"/en-ca/locations/","openInNewWindowText":null},{"text":"Global Behind the science magazine","href":"https://www.gsk.com/en-gb/behind-the-science/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSKPro for healthcare professionals","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK Medical for healthcare professionals","href":"https://medical.gsk.com/en-ca/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/en-ca/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Supplier website","href":"https://supplier.gsk.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Company","href":"/en-ca/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-ca/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-ca/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-ca/responsibility/","openInNewWindowText":null},{"text":"Media","href":"/en-ca/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-ca/careers/","openInNewWindowText":null}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-ca/contact-us/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-ca/products/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-ca/responsibility/accessibility/","target":"_parent","openInNewWindowText":"Opens in a new window"},{"text":"Terms of use","href":"/en-ca/terms-of-use/","target":"_parent","openInNewWindowText":"Opens in a new window"},{"text":"Cookie policy","href":"/en-ca/cookie-policy/","target":"_parent","openInNewWindowText":"Opens in a new window"},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-ca/privacy-notice/general/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Sitemap","href":"/en-ca/sitemap/","openInNewWindowText":null}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"GSK’s AREXVY has been approved in Canada for the prevention of lower respiratory tract disease (LRTD).","og":[{"property":"og:title","content":"Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk"},{"property":"og:description","content":"GSK’s AREXVY has been approved in Canada for the prevention of lower respiratory tract disease (LRTD)."},{"property":"og:image","content":"https://ca.gsk.com/media/rsznn1hu/packing2.jpg?width=600&format=webp&quality=100&v=1dbf19a78b5ce80"},{"property":"og:url","content":"https://ca.gsk.com/en-ca/media/press-releases/expanded-age-indication-for-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-approved-in-canada-for-adults-aged-50-59-at-increased-risk/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk"},{"name":"twitter:description","content":"GSK’s AREXVY has been approved in Canada for the prevention of lower respiratory tract disease (LRTD)."},{"name":"twitter:image","content":"https://ca.gsk.com/media/rsznn1hu/packing2.jpg?width=600&format=webp&quality=100&v=1dbf19a78b5ce80"},{"name":"twitter:url","content":"https://ca.gsk.com/en-ca/media/press-releases/expanded-age-indication-for-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-approved-in-canada-for-adults-aged-50-59-at-increased-risk"}]},"stickyShare":null,"exitSitePreferences":{"popupEnabled":true,"title":"You are leaving our website","texts":"The information you are about to be referred to may not comply with the local regulatory requirements. Further information relevant to the local environment is available from the company or via the Product Information.
","continueText":"Continue","cancelText":"Cancel","exclusionUrls":["http://gsk.com/","https://www.gsk.com","https://innovation.gsk.com/","https://www.gskgrants.com","https://www.gskforyou.com/","https://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","http://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","https://www.gsk.com/en-gb/products/stiefel-dermatology/","https://www.gsk.com/en-gb/products/viiv-healthcare/","https://www.contactus.gsk.com/callback/index.html","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsksource.com/pharma/content/gsk/source/us/en.html","http://www.msds-gsk.com/","https://www.gsk.com/en-gb/investors/shareholder-information/","http://www.gsk.com/en-gb/investors/","https://www.gsk.com/en-gb/investors/corporate-reporting/","https://www.gsk.com/en-gb/investors/product-pipeline/","http://www.gskgrants.com/","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsk.com/media/2941/human-rights-statement-policy.pdf","http://www.gsk.com/media/280848/human-rights-statement-policy.pdf","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","http://twitter.com/GSK","http://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/media/press-releases/new-multi-country-survey-reveals-need-for-improved-awareness-around-long-term-impact-and-appropriate-use-of-corticosteroids-in-sle-management/","http://www.gskforyou.com/","https://www.gskforyou.com/prescription-resource-assistance/immunology-respiratory/","https://www.contactus.gsk.com/callback.html","https://www.gsk.com/en-gb/about-us/governance/global-compliance/","https://www.gsk.com/en-gb/careers/physicians/","https://www.gsk.com/en-gb/contact-us/worldwide/","https://access.gsk.com/password/","https://access.gsk.com/selfservice/static/login.jsp?TYPE=33554433&REALMOID=06-c7edf5ec-5585-100d-83b1-84797f88fc89&GUID=&SMAUTHREASON=0&METHOD=GET&SMAGENTNAME=-SM-90R5K5a0NsTyKRhPyTIn3A3B5ovKkqcehflGRUrUNusjZdRaPY%2bWUozEFizs1bMg&TARGET=-SM-https%3a%2f%2fuksah%2egsk%2ecom%2fswh_uk_win_ns%2fcommunications%2femployee%2femployees%2ehtm","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://ascend.cvmsolutions.com/Account/Login?client=gsk","https://www.gsk.com/media/5097/our-approach-to-responsible-business_sept-18.pdf","https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/","https://www.gsk.com/media/2538/gsk-materiality-process.pdf","https://www.gsk.com/en-gb/responsibility/access-to-healthcare/","https://www.gsk.com/en-gb/responsibility/our-people/","https://www.gsk.com/en-gb/responsibility/environment/","https://www.gsk.com/en-gb/responsibility/operating-responsibly/","https://www.gsk.com/media/4552/our-code-of-practice.pdf","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=10","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.gsk.com/en-gb/media/resource-centre/","https://www.gsk.com/en-gb/media/image-and-video-library/","https://www.gsk.com/en-gb/media/rss-feeds/","https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2017/","https://www.gsk.com/en-gb/careers/experienced-professionals/business-operations/","https://www.gsk.com/en-gb/careers/experienced-professionals/engineering/","https://www.gsk.com/en-gb/careers/experienced-professionals/manufacturing-and-supply/","https://www.gsk.com/en-gb/careers/experienced-professionals/marketing-and-communications/","https://www.gsk.com/en-gb/careers/experienced-professionals/research-and-development/","https://www.gsk.com/en-gb/careers/experienced-professionals/sales/","https://www.gsk.com/media/5041/rd-update-slides-hal-barron.pdf","https://www.gsk.com/en-gb/careers/meet-our-people/","https://www.gsk.com/en-gb/responsibility/our-people/employee-volunteering/","https://gskearlytalent.avature.net/landingpage","https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/future-leaders-graduate-programme/","https://www.gsk.com/en-gb/responsibility/our-people/volunteer-stories/","https://www.gsk.com/en-gb/partnerships/bioelectronics-research-network/","https://www.gsk.com/en-gb/research/our-approach/open-innovation/","https://www.youtube.com/channel/UChWuz9ZDceHYHXmJVJ4hF8Q","https://www.youtube.com/channel/UCN1XeWQWLVhFLHQwZl93jFQ","https://www.youtube.com/channel/UCwQyIfV4pLlsZGuN7fiZm2w","https://www.gsk.com/en-gb/media/press-releases/karenann-terrell-appointed-chief-digital-technology-officer-gsk/","https://www.gsk.com/en-gb/careers/meet-our-people/lindsay-rd-uk/","http://uk.gsk.com/en-gb/careers/apprenticeships/","https://www.gsk.com/media/4931/gsk-quick-facts.pdf","https://ie.gsk.com/ie/careers/apprenticeships/","http://au.gsk.com/en-au/careers/apprenticeships/","http://sg.gsk.com/en-sg/careers/","https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/","https://gsk.i-sight.com/landing-page/","https://www.gskforyou.com/","https://privacy.gsk.com/en-ca/privacy-notice/general","http://annualreport.gsk.com/","https://privacy.gsk.com","https://www.gsk.com/en-gb/company/outstanding-people/","https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-fy-2021-reported-sales-of-34-billion-stable-at-aer-plus5-cer/","https://www.gsk.com/media/7473/esg-performance-report-2021.pdf","https://www.gsk.com/en-gb/behind-the-science/","https://gskpro.com/","https://viivhealthcare.com/","https://gsk.supplierone.co/","https://www.gsk.com/speakup","https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/","https://www.gsk.com/en-gb/research-and-development/our-approach-to-rd/","https://www.gsk.com/en-gb/innovation/partnerships/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/infectious-diseases/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/hiv/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/oncology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/immunology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/opportunity-driven/","https://www.gsk.com/media/8519/the-code-printable-version.pdf","https://www.gsk.com/en-gb/company/policy-positions","https://www.gsk.com/en-gb/company/codes-standards-and-reports","https://www.gsk.com/en-gb/innovation/pipeline/","https://www.gsk.com/en-gb/innovation/rd-locations/","https://www.gsk.com/en-gb/innovation/research-and-development-approach/","https://www.gsk-studyregister.com","https://gskpro.com/en-ca/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/pricing-and-access/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/diversity-equity-and-inclusion/","https://www.gsk.com/en-gb/responsibility/environmental-sustainability/","https://www.gsk.com/en-gb/responsibility/product-governance/","https://www.gsk.com/en-gb/responsibility/ethical-standards/","https://annualreport.gsk.com/","https://www.gsk.com/en-gb/media/media-contacts/","https://www.gsk.com/en-gb/media/media-library/","https://www.gsk.com/en-gb/media/social-media/","https://www.gsk.com/en-gb/media/our-response-to-the-situation-in-ukraine/","https://www.gsk.com/en-gb/careers/featured-careers/","https://www.gsk.com/en-gb/careers/how-we-hire/","https://www.gsk.com/en-gb/careers/our-global-and-regional-hubs/","https://www.gsk.com/en-gb/careers/how-we-hire/frequently-asked-questions/","https://www.gsk.com/en-gb/careers/","https://www.gsk.com/en-gb/careers/early-talent/kickstart-your-career/","https://www.gsk.com/en-gb/careers/early-talent/apprentice-programmes/","https://www.gsk.com/en-gb/careers/early-talent/work-experience-placements-and-internships/","https://www.gsk.com/en-gb/company/governance/compliance/","https://gskpro.com","https://www.gsk-studyregister.com/","https://www.gsk.com/en-gb/company/gsk-at-a-glance/","https://www.gsk.com/en-gb/innovation/technologies/","https://www.gsk.com/en-gb/innovation/trials/diversity-in-clinical-trials/","https://www.gsk.com/en-gb/responsibility/","https://www.gsk.com/en-gb/careers/early-talent/future-leaders-graduate-programme","https://privacy.gsk.com/en-ca/privacy-notice/","https://us.gsk.com/en-us/about-us/us-community-partnerships/stem-education/philadelphia-stem-equity-collective/","https://www.gsk.com/en-gb/responsibility/charitable-partnerships/","https://supplier.gsk.com/irj/portal/public","https://privacy.gsk.com/en-ca/privacy-notice/general/","https://twitter.com/gskca","https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2022-performance-with-full-year-sales-of-293-billion/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/respiratoryimmunology/","https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2023/","https://www.gsk.com/en-gb/responsibility/environment/climate/","https://supplier.gsk.com/"]},"settings":{"optionalStylesheetLink":"/media/bbcob5qx/optional_style_ca.css","themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://ca.gsk.com/media/s3hkylbc/gsk-logo_png.png?width=104&format=webp&quality=100&v=1dbf19a937d1f70","alt":"Gsk Logo Png","darkModeSrc":"https://ca.gsk.com/media/s3hkylbc/gsk-logo_png.png?width=104&format=webp&quality=90&v=1dbf19a937d1f70"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK Canada"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://ca.gsk.com/en-ca/media/press-releases/expanded-age-indication-for-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-approved-in-canada-for-adults-aged-50-59-at-increased-risk/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":null,"protectedPage":false,"schema":null}